The reason for regimen change among HIV/AIDS patients initiated on first line highly active antiretroviral therapy in southern ethiopia

North American Journal of Medical Sciences

Volumn 4, Issue 1, 2012, Pages 19-23

  Woldemedhin, Beharu ^a   Wabe, Nasir Tajure ^b  

^a DILLA UNIVERSITY   (Ethiopia)

^b JIMMA UNIVERSITY   (Ethiopia)

Author keywords

Ethiopia; HAART; Initial regimen; Switch; Toxicity

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; AIDS PATIENT; ANEMIA; CD4 LYMPHOCYTE COUNT; CHILD; COMORBIDITY; CROSS-SECTIONAL STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; ETHIOPIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NIGHTMARE; PERIPHERAL NEUROPATHY; PREGNANCY; RASH; RETROSPECTIVE STUDY; REVIEW; SLEEP DISORDER; SUBSTITUTION THERAPY; TOXICITY; TREATMENT DURATION; TREATMENT WITHDRAWAL;

EID: 84857152715     PISSN: None     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.92898     Document Type: Review

References (24)

1. World Health Organization, UNAIDS, UNICEF: Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector Progress Report. WHO; 2007.
2. UNAIDS/WHO: Report on AIDS epidemic, 2006. Available from: http://www.unaids.org/en/HIV-date/2006/Global Report/default.ads). [Last accessed on Dec 2009].
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
4. UNAIDS/WHO: AIDS Epidemic update Dec, 2009. Available from: http://www.da.unaids.org/pub/Report/2009/2009-epidemicupdate-en.pdf). [Last accessed on Dec 2009].
5. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the Euro SIDA study: An observational study. Lancet 2004;362:22-9.
6. Ethiopian People Living with HIV/AIDS-PLWHA, 2009. Available from: http://www.etharc.org/plwha/index.htm.) [Last accessed on Dec 2009].
7. Hammer SM. Increasing choices for HIV therapy. N Engl J Med 2002;346:2022-3.
8. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-41.
9. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564-73.
10. Drug administration and control Authority of Ethiopia, standard treatment guidelines. Ethiopia; 2004. p. 1-3.
11. Ethiopian federal ministry of health; guideline for implantation of the antiretroviral therapy program in Ethiopia. 2007.
12. Hart E, Curtis H, Wilkins E, Johnson M. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral naïve patients. HIV Med 2007;8:186-91.
13. Eichetebaum. Pharmacokinetic interaction between ARVs and other drugs in HIV seroposetives. AIDS 2002; 41:577-96.
14. Timothy W, Marshall G, Roy M. HIV insight knowledge base chapter changing Antiretroviral Therapy: Why, when and how. J Acquir Immune Defic Syndr 2006;12:782-9.
15. Ammassari A. Self reported symptoms and medication side effects influence adherence to HAART in persons with HIV infections. J Acquir Immune Defic Syndr 2001;28:445-9.
16. Kumara SN, Vallabhaneni S. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006;41:53-8.
17. Kiguba MN. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: Prevalence and Associated factors. J Acquir Immune Defic Syndr 2007;45:218-23.
18. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000;14:499-507.
19. Dorrucci M, Pezzotti P, Grisorio B, Minardi C, Muro MS, Vullo V, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: A comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001;15:1733-6.
20. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001;15:185-94.
21. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407-14.
22. Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, et al. Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America. PLoS ONE 2010;5:1-10.
23. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-31.
24. Mess OU, Eupene N, Anglaret Y. Antiretroviral treatment changes in adults from Cote d'lvoire: The role of tuberculosis and pregnancy. AIDS 2010;24:93-9.